{
    "clinical_study": {
        "@rank": "53798", 
        "acronym": "ERASER", 
        "arm_group": {
            "arm_group_label": "Intravitreal ranibizumab 0.3mg", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Performance assessment testing may be a useful tool to evaluate the impact of ranibizumab on\n      day-to-day visual function in patients with Diabetic Macular Edema (DME)."
        }, 
        "brief_title": "Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab", 
        "condition": "Diabetic Macular Edema", 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Macular Edema"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ability to provide written informed consent and comply with study assessments for the\n             full duration of the study\n\n          -  Age 18 \u2264 x \u2264 65 years and currently employed at the baseline study visit\n\n          -  Diagnosis of diabetes mellitus (type 1 or 2)\n\n             o Any one of the following will be considered to be sufficient evidence that diabetes\n             is present:\n\n          -  Current regular use of insulin for treatment of diabetes\n\n          -  Current regular use of oral anti-hyperglycemia agent for the treatment of diabetes\n\n          -  Clinical evidence of retinal thickening due to macular edema involving the center of\n             the macula, associated with diabetic retinopathy.\n\n          -  Central diabetic macular edema present on clinical examination or or evidence\n             indicating disease activity on spectral domain OCT.\n\n          -  Visual acuity score greater than or equal to 19 letters (20/400) and less than or\n             equal to 73 letters (20/40) by the ETDRS visual acuity protocol.\n\n          -  Media clarity, pupillary dilation and patient cooperation sufficient to allow OCT\n             testing and retinal photography\n\n        Exclusion Criteria:\n\n          -  Pregnancy (positive pregnancy test) or known to be pregnant; also pre-menopausal\n             women not using adequate contraception.\n\n          -  Participation in another ocular investigation or trial simultaneously\n\n          -  Blood pressure > 180/110 (systolic above 180 OR diastolic above 110)\n\n          -  Any condition that, in the opinion of the investigator, would preclude participation\n             in the study (e.g. chronic alcoholism, drug abuse)\n\n          -  Evidence of vitreoretinal interface abnormality after ocular exam or OCT that may be\n             contributing to the macular edema\n\n          -  An eye that, in the investigator's opinion, has no chance of improving in visual\n             acuity following resolution of macular edema (e.g. presence of  subretinal fibrosis\n             or geographic atrophy)\n\n          -  Presence of another ocular condition that may affect the visual acuity or macular\n             edema during the course of the study (e.g. AMD, uveitis, Irvine-Gas)\n\n          -  Evidence of active neovascularization of the iris or retina\n\n          -  Evidence of central atrophy or fibrosis in the study eye\n\n          -  Presence of substantial cataract, one that might decrease the vision by 3 or more\n             lines of vision at sometime during the study.\n\n          -  Previous use of intraocular or periocular corticosteroids in the study eye (if\n             bilateral DME, both eyes must be treatment na\u00efve)\n\n          -  Previous treatment with anti-angiogenic drugs in the study eye i.e. pegaptanib\n             sodium, bevacizumab, ranibizumab, aflibercept (if bilateral DME, both eyes must be\n             treatment na\u00efve)\n\n          -  History of vitreous surgery in the study eye\n\n          -  History of cataract surgery within 3 months of enrollment.\n\n          -  History of YAG capsulotomy within 2 months of enrollment.\n\n          -  Visual acuity <20/400 in the fellow eye\n\n          -  Uncontrolled glaucoma (pressure >30) despite treatment with glaucoma medications.\n\n          -  History of cerebral vascular accident or myocardial infarction within 3 months prior\n             to Day 0."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02107131", 
            "org_study_id": "ML29184s"
        }, 
        "intervention": {
            "arm_group_label": "Intravitreal ranibizumab 0.3mg", 
            "intervention_name": "Intravitreal ranibizumab 0.3mg", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 4, 2014", 
        "location": [
            {
                "contact": {
                    "email": "crcjgiust@yahoo.com", 
                    "last_name": "Jack Giust, BS", 
                    "phone": "661-325-4393"
                }, 
                "facility": {
                    "address": {
                        "city": "Bakersfield", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93039"
                    }, 
                    "name": "California Retina Consultants - Bakersfield"
                }, 
                "investigator": {
                    "last_name": "Nathan Steinle, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "melrabena@californiaretina.com", 
                    "last_name": "Melvin Rabena, BS", 
                    "phone": "805-963-1648", 
                    "phone_ext": "31"
                }, 
                "facility": {
                    "address": {
                        "city": "Santa Barbara", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93103"
                    }, 
                    "name": "California Retina Consultants - Santa Barbara Office"
                }, 
                "investigator": {
                    "last_name": "Nathan Steinle, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Evaluation of ReAding Speed, Contrast Sensitivity, and Work Productivity in Working Individuals With Diabetic Macular Edema Following Treatment With Intravitreal Ranibizumab", 
        "overall_contact": {
            "email": "melrabena@californiaretina.com", 
            "last_name": "Melvin Rabena, BS", 
            "phone": "805-963-1648", 
            "phone_ext": "31"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the mean change in maximum reading speed on MNREAD reading acuity charts (binocular reading) and SST reading cards (monocular reading) from baseline.", 
            "measure": "Maximum Reading Speed", 
            "safety_issue": "No", 
            "time_frame": "Month 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02107131"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate the mean change in work productivity and activity impairment from baseline using work productivity and activity impairment questionairre.", 
                "measure": "Change in work productivity", 
                "safety_issue": "No", 
                "time_frame": "Month 12"
            }, 
            {
                "description": "To determine the mean change in best-corrected visual acuity on ETDRS visual acuity chart at a starting distance of 4 meters from baseline", 
                "measure": "Change in visual acuity", 
                "safety_issue": "No", 
                "time_frame": "Month 12"
            }, 
            {
                "description": "To measure the mean change in contrast sensitivity scores on Pelli-Robson charts from baseline.", 
                "measure": "Change in contrast sensitivity", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "California Retina Consultants", 
        "sponsors": {
            "collaborator": {
                "agency": "California Retina Research Foundation", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "California Retina Consultants", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}